The authors of the commentary argue that biased studies funded by pharmaceutical companies tend to produce favorable outcomes for their products, raising questions about the real efficacy and safety of GLP-1 drugs.
They highlight that sponsorship bias can lead not only to skewed academic outcomes but also to media narratives and public beliefs that may overlook significant side effects such as gastrointestinal distress.
Furthermore, the commentary emphasizes the financial burden of semaglutide, criticizing its high cost which limits access for underserved communities, necessitating a call for better funding in objective research.
To combat misinformation around GLP-1s, the specialists urge that social media posts should be labeled with disclaimers and accompanied by health information from reliable sources like the NIH and FDA.
Collection
[
|
...
]